Quantitative Evaluation of the Use of Non-Steroidal Anti-Inflammatory Drugs in Patients with Chronic Kidney Disease at Outpatient Units in a University Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To quantitatively evaluate the use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with chronic kidney disease (CKD) in outpatient units of a university hospital. Methods: The study was a retrospective descriptive study in CKD patients receiving NSAIDs for the first time from the hospital during January 1-December 31, 2014. The data on NSAIDs use were collected from hospital database and the review of medical records. Results: 12.27% CKD patients in outpatient units of the hospital received NSAIDs, while 11.63% of those in stage 3-5 received NSAIDs exceeding the target goal set by the Rational Drug Use Hospital (RDU hospital) project in which should less than 10.0%. There were 353 CKD patients who received NSAIDs for the first time from the hospital. Majority of this group of subjects aged 65 years old or over (67.14%), were female (52.12%) and were in CKD stage 3 (79.60%). The most commonly prescribed NSAIDs were etoricoxib, naproxen and celecoxib (27.18, 20.77 and 18.46% respectively). The departments with the highest numbers of NSAIDs prescribing were orthopedics, internal medicine and surgery (37.77, 25.27 and 13.83% respectively). NSAIDs were prescribed to relieve bone and joint pain, muscle pain and unidentified pain. The majority of CKD patients received NSAIDs for one time only (71.95%) with an average of 1.41 time per person per year. The most commonly prescribed NSAIDs were selective cyclooxygenase (COX) 2 inhibitors (57.69%). 30.59% of CKD patients received NSAIDs for more than 14 days. Moreover, the type of prescribed NSAIDs and duration of drug use were independent to the stages of CKD. Conclusion: NSAIDs use in CKD patients in outpatient units was higher than the target goal in the RDU hospital project, and long term use of NSAIDs was identified in some patients. Quantitative evaluation of drug use revealed the current situation on NSAIDs use in CKD patients, and provided the information for development the measures to promote rational drug use in the future.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. United States Renal Data System. 2017 USRDS chapter 6: health care expenditures for persons with CKD. Am J Kidney Dis. 2018;71:S117-S36.
3. Keith DS, Nichols GA, Gullion CM, Brown J, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-63.
4. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephro. 2010;5:1558-65.
5. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11:e0148765.
6. Centers for Disease Control and Prevention. Chronic kidney disease surveillance system-United States [online]. 2018 [cited Mar 2, 2018]. Available from: www.cdc.gov/ckd.
7. Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010;25:1567-75.
8. Rational drug use subcommittee. Rational drug use hospital manual. Nonthaburi: The Agricultural Cooperative Federation of Thailand; 2015.
9. Horl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals. 2010;3:2291-321.
10. Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. Am J Kidney Dis. 2017;69:451-60.
11. World Health Organization. Drug and therapeutics committees-a practical guide [online]. 2003 [cited Dec 6, 2017]. Available from: apps.who.int/medicine docs/pdf/s4882e/s4882e.pdf.
12. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30:247-55.
13. Plantinga L, Grubbs V, Sarkar U, Hsu CY, Hedgeman E, Robinson B, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011;9:423-30.
14. Heleniak Z, Cieplinska M, Szychlinski T, Rychter D, Jagodzinska K, Klos A, et al. Nonsteroidal anti- inflammatory drug use in patients with chronic kidney disease. J Nephrol. 2017;30:781-6.
15. Adams RJ, Appleton SL, Gill TK, Taylor AW, Wilson DH, Hill CL. Cause for concern in the use of non-steroidal anti-inflammatory medications in the community-a population-based study. BMC Fam Pract. 2011;12:70.
16. Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PloS one. 2014;9:e89072.
17. Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dialysis. 2014;27:188-204.
18. Pham PC, Khaing K, Sievers TM, Pham PM, Miller JM, Pham SV, et al. 2017 update on pain manage ment in patients with chronic kidney disease. Clin Kidney J. 2017;10:688-97.
19. Chou CI, Shih CJ, Chen YT, Ou SM, Yang CY, Kuo SC, et al. Adverse Effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitaliza- tion for acute kidney injury: a nested case-control cohort study. Medicine. 2016;95:e2645.
20. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observa- tional studies. Euro J Intern Med. 2015;26:285-91.
21. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
22. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. New Engl J Med. 2004;351:2187-94.
23. Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, et al. The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada. Health Policy. 2007;84:1-13.
24. Wei L, MacDonald TM, Jennings C, Sheng X, Flynn RW, Murphy MJ. Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function. Kidney Int. 2013;84:174-8.
